Paradigm Biopharmaceuticals Limited Share Price
Equities
PAR
AU000000PAR5
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 AUD | +5.88% | -5.26% | -36.47% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 89.34M 137M 7.46B |
---|---|---|---|---|---|
Net income 2024 * | -52M -79.71M -4.34B | Net income 2025 * | 12M 18.39M 1B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.42
x | P/E ratio 2025 * |
6.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.7% |
1 day | +5.88% | ||
1 week | -5.26% | ||
Current month | -21.74% | ||
1 month | -22.86% | ||
3 months | -28.00% | ||
6 months | -34.94% | ||
Current year | -36.47% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 02/14/02 |
Abby Macnish
DFI | Director of Finance/CFO | - | 30/22/30 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 01/19/01 |
Paul Rennie
CEO | Chief Executive Officer | - | 02/14/02 |
Amos Meltzer
BRD | Director/Board Member | 58 | 09/20/09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 0.27 | +5.88% | 1 047 046 |
29/24/29 | 0.255 | -5.56% | 1,474,557 |
26/24/26 | 0.27 | -5.26% | 455,715 |
24/24/24 | 0.285 | 0.00% | 311,490 |
23/24/23 | 0.285 | 0.00% | 122,248 |
Delayed Quote Australian S.E., April 30, 2024 at 11:40 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.47% | 58.6M | |
+1.77% | 42.86B | |
+47.02% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- PAR Stock